Big Japanese Pharmas Plan R&D Push As Patents Expire
This article was originally published in PharmAsia News
Japan's largest pharmaceuticals are investing heavily in research and development, chasing their next new drug in advance of expiring patent protection on some of their best-sellers that begins next year. Astellas plans a 6 percent increase despite a decreasing profit this year, Daiichi Sankyo and Eisai see R&D increases of 5 percent, each, and Takeda Pharmaceutical, the largest of the four, plans a 6 percent increase in its R&D budget. All but Eisai have major drugs in Phase III testing, while Eisai looks for something in the field of cancer, thanks to its acquisition of MGI Pharma of the United States. (Click here for more - a subscription may be required
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.